Aion Therapeutic Acquires Toppen Health Inc.
December 15, 2023
Aion Therapeutic Inc. completed the acquisition of all outstanding shares of Toppen Health Inc., a Sanford, Florida-based manufacturer of water filtration systems, pursuant to share purchase agreements dated October 2023. The transaction was satisfied by the issuance of CAD $10,000,000 in common shares and includes a potential US $2,000,000 earn-out tied to revenue targets; Toppen operates a 7,500 sq-ft manufacturing facility and has eight employees.
- Buyers
- Aion Therapeutic Inc.
- Targets
- Toppen Health Inc.
- Sellers
- Toppen shareholders
- Industry
- Manufacturing
- Location
- Florida, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Eilean Therapeutics Acquires Ness Therapeutics
March 4, 2024
Biotechnology
Eilean Therapeutics LLC acquired Ness Therapeutics Inc in an all-equity transaction to obtain Ness’s preclinical PTPN2 inhibitor program. The acquisition expands Eilean’s immuno-oncology pipeline and capabilities in small-molecule inhibitors targeting resistance mechanisms in hematologic and solid malignancies.
-
PAI Partners Acquires Apleona from EQT for ~€1.6bn
December 6, 2020
Industrial Services
PAI Partners has agreed to acquire Apleona Group GmbH from EQT (EQT VII) for approximately EUR 1.6 billion. Apleona, headquartered in Neu-Isenburg, Germany, is a leading European technical and integrated facility management provider with more than 20,000 employees and a strong position in the DACH region; PAI said it will pursue further consolidation and growth both organically and via M&A.
-
Nordson Corporation to Acquire Atrion Corporation
May 28, 2024
Medical Devices
Nordson Corporation has entered into a definitive agreement to acquire Atrion Corporation for $460.00 per share in cash, representing an aggregate enterprise value of approximately $800 million. The acquisition expands Nordson's medical portfolio into infusion and cardiovascular therapies and is expected to close prior to Nordson's fiscal year-end 2024, subject to regulatory and stockholder approvals.
-
Shionogi Acquires Tetra Therapeutics
May 26, 2020
Biotechnology
Shionogi & Co., Ltd. agreed to acquire clinical-stage biopharmaceutical company Tetra Therapeutics, giving Shionogi global rights to Tetra's portfolio including BPN14770. The deal, announced May 26, 2020, is valued at up to $500 million in milestone and contingent payments.
-
Ionis Pharmaceuticals to Acquire Remaining Stake in Akcea Therapeutics
August 31, 2020
Biotechnology
Ionis Pharmaceuticals agreed to acquire the approximately 24% of Akcea Therapeutics it does not already own for $18.15 per share in cash, implying a fully diluted transaction value of about $500 million. The deal will be executed via a tender offer followed by a second-step merger, and Ionis expects to complete the transaction in Q4 2020 to consolidate Akcea's pipeline, commercial products and cash while realizing cost synergies.
-
KAKEN Pharmaceutical Acquires Aadi Subsidiary from Whitehawk Therapeutics for $100M
March 26, 2025
Pharmaceuticals
Whitehawk Therapeutics has completed the divestiture of Aadi Subsidiary, Inc. to KAKEN Pharmaceutical Co., Ltd. for $100 million in cash plus customary adjustments. KAKEN assumes ownership of the Aadi Bioscience name, trademarks and the FYARRO business; Whitehawk expects to use proceeds (together with a recent $100M PIPE) to fund its ADC pipeline and extend its cash runway into 2028.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.